Novartis Invests €200 Million in Ljubljana Plant for Biologics and RNA Drugs
Novartis has announced a significant investment of 200 million euros in its factory located in Ljubljana, Slovenia. This investment is dedicated to establishing a new aseptic manufacturing facility. The plant will be responsible for filling biological medicines and drugs based on RNA technology. The new facility is expected to create employment opportunities for approximately 300 specialists. This expansion underscores Novartis' commitment to advancing its capabilities in producing complex and innovative pharmaceutical products.
This strategic investment by Novartis in its Ljubljana facility highlights a growing trend in pharmaceutical manufacturing towards specialized production of biologics and RNA-based therapies. The substantial capital expenditure signals confidence in the region's capacity to support advanced biopharmaceutical operations and workforce development. Such facilities are crucial for meeting the increasing global demand for these cutting-edge treatments. The expansion also positions Slovenia as a key player in the European pharmaceutical landscape, potentially attracting further investment and fostering local expertise in a high-growth sector.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.